Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma

Loggie, Brian W.; Fleming, Ronald A.; McQuellon, Richard P.; Russell, Gregory B.; Geisinger, Kim R.; Levine, Edward A.
October 2001
American Surgeon;Oct2001, Vol. 67 Issue 10, p999
Academic Journal
Malignant peritoneal mesothelioma (MPM) is a rare and often rapidly fatal disease with median survival of 5 to 12 months for untreated cases and 16 months reported after multimodality treatment. We report a prospective clinical treatment study using cytoreductive surgery combined with intraoperative intraperitoneal heated chemotherapy (IPHC) perfusion using mitomycin C for MPM. Twelve patients (11 male with a mean age 51 years) were treated. Seven patients presented with bulky disease and seven with ascites. All underwent exploratory laparotomy with histologically confirmed diagnosis of MPM. Surgical debulking as feasible was performed. Complete gross tumor removal was possible in only one patient. Cytoreduction was followed by a 2-hour closed low-volume IPHC using mitomycin C. One patient died 50 days postoperatively from complications relating to small bowel perforation. Hematologic toxicity of the procedure was minimal. Ascites was controlled in all patients and permanently in 86 per cent of patients presenting with ascites. To date median survival is 34.2 months with median follow-up of 45.2 months. One patient was re-explored for ventral hernia 2 years post-IPHC, had negative peritoneal biopsies, and remains disease-free at 5 years. Given the dismal prognosis associated with MPM the results of treatment with cytoreductive surgery combined with IPHC perfusion are encouraging. The rarity of MPM makes appropriately powered prospective randomized trials unlikely. Therefore, we now offer this approach off protocol; however, further study of this combined modality therapy is warranted.


Related Articles

  • Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Tomek, S; Emri, S; Krejcy, K; Manegold, C // British Journal of Cancer;1/27/2003, Vol. 88 Issue 2, p167 

    This review summarises the results of previously conducted clinical trials, and subsequently presents data arising from all phase II-III studies on chemotherapy of malignant pleural mesothelioma (MPM) published since the last relevant overview. While response rates exceeding 30% have barely been...

  • Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Byeong-Bae Park; Young-Hyuck Im; In Hwang; Sang Lee; Jin Ahn; Myung-Ju Ahn; Ho-Yeong Lim; Won Kang; Keunchil Park // Investigational New Drugs;Aug2008, Vol. 26 Issue 4, p387 

    Summary  The patients with metastatic or recurrent esophageal cancer are incurable. A number of patients who progress after first-line chemotherapy may still be fit for second-line treatment. However, there is no currently established effective and tolerable salvage chemotherapy. We...

  • Mitomycin-C for pterygia: Panacea or Pandora's box? Galler // Ophthalmology Times;12/01/99, Vol. 24 Issue 23, p8 

    Focuses on the uncertainty over the use of mitomycin C for treating pterygium. Description of the effectiveness of topical use of mitomycin C in 1963; Safety of the substance according to research findings; Significance of its safety on its use before and after surgery.

  • Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Vogl, Thomas J.; Zangos, Stephan; Eichler, Katrin; Selby, J. Bayne; Bauer, Ralf W. // European Radiology;Mar2008, Vol. 18 Issue 3, p468 

    To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy. Between 2002 and 2006, 55 patients were treated in 4-week intervals (mean...

  • 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer. MacDonald, John S.; Schein, Philip S.; Whooley, Paul V.; Smythe, Tarilyn; Ueno, Winston; Hoth, Daniel; Smith, Frederick; Boiron, Michel; Gisselbrecht, Christian; Brunet, Rene; Legarde, Claude // Annals of Internal Medicine;Oct80, Vol. 93 Issue 4, p533 

    Presents a study which described a clinical trial of a combination chemotherapy program using 5-fluorouracil, doxorubicin, and mitomycin for advanced gastric cancer. Incidence of gastric carcinoma in the U.S.; Materials and methods used; Results; Discussion.

  • Study of cytogenetical effects of chemotherapeutic agents Mitomycin C and Cisplatin on normal Somatic and Germ cells: An in vivo study. Mazumdar, Mehnaz; Giri, Sarbani; Roy, Saptadeepa // International Journal of PharmTech Research;Jan-Mar2012, Vol. 4 Issue 1, p61 

    The chemotherapeutic drugs available in the market are not specified to eliminate only cancer cells but leads to numerous toxic physical, cytogenetical and physiological side effects. Since the common target of all anticancer drugs is to decrease the growth rate (cell division) of the cancer...

  • EORTC Protocol 22011--40014.  // Oncologie;sep2004 Supplement 7, Vol. 6, pS186 

    Presents information on a clinical trial on the use of mitomycin C and cisplatin as chemotherapy for anal cancer. Experimental procedure; Results; Objectives.

  • Bladder Cancer.  // Current Medical Literature: Urology;2009, Vol. 15 Issue 3, p88 

    The article discusses research on bladder cancer. It references several studies including the effectiveness of a sequential treatment approach to myoinvasive urothelial cancer by P. N. Lara et al, the outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom...

  • Interstitial pneumonitis following intrapleural chemotherapy. Zappa, Luis; Savady, Renaldo; Humphries, Gary N.; Sugarbaker, Paul H. // World Journal of Surgical Oncology;2009, Vol. 7, p1 

    Background: Mucinous neoplasms within the abdomen may disseminate by direct extension through the diaphragm to involve the pleural space. Treatment of this condition is by parietal and visceral pleurectomy followed by hyperthermic intrapleural chemotherapy. Case presentation: In this case report...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics